Zevra Non Current Assets Total vs Current Deferred Revenue Analysis
| ZVRA Stock | 9.49 0.10 1.04% |
Zevra Therapeutics financial indicator trend analysis is more than just analyzing Zevra Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zevra Therapeutics is a good investment. Please check the relationship between Zevra Therapeutics Non Current Assets Total and its Current Deferred Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.
Non Current Assets Total vs Current Deferred Revenue
Non Current Assets Total vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zevra Therapeutics Non Current Assets Total account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.
The correlation between Zevra Therapeutics' Non Current Assets Total and Current Deferred Revenue is 0.34. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Zevra Therapeutics, assuming nothing else is changed. The correlation between historical values of Zevra Therapeutics' Non Current Assets Total and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Zevra Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Non Current Assets Total i.e., Zevra Therapeutics' Non Current Assets Total and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.34 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Zevra Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zevra Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.At present, Zevra Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.39, whereas Tax Provision is forecasted to decline to (35.7 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 28.7M | 10.5M | 27.5M | 20.4M | Interest Income | 248K | 760K | 4.6M | 4.8M |
Zevra Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Zevra Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zevra Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.5M | 11.2M | 132.9M | 115.5M | 172.3M | 180.9M | |
| Other Current Liab | 236K | 5.5M | 3.3M | 3.3M | 13.2M | 13.9M | |
| Total Current Liabilities | 5.4M | 7.5M | 4.2M | 11.7M | 73.7M | 77.4M | |
| Total Stockholder Equity | (74.5M) | (66.4M) | 127.1M | 85.8M | 61.9M | 65.0M | |
| Property Plant And Equipment Net | 3.0M | 2.4M | 2.0M | 1.8M | 1.5M | 1.6M | |
| Net Debt | 76.3M | 66.1M | (110.8M) | (51.3M) | 716K | 680.2K | |
| Retained Earnings | (245.7M) | (258.5M) | (267.0M) | (308.6M) | (399.8M) | (379.8M) | |
| Accounts Payable | 1.1M | 1.2M | 516K | 3.6M | 14.0M | 14.7M | |
| Cash | 3.2M | 4.2M | 112.3M | 65.5M | 43.0M | 29.5M | |
| Non Current Assets Total | 3.9M | 2.8M | 17.9M | 22.5M | 85.4M | 89.7M | |
| Non Currrent Assets Other | 562K | 527K | 438K | 724K | 9.9M | 10.4M | |
| Cash And Short Term Investments | 3.2M | 4.2M | 112.3M | 82.8M | 43.0M | 40.6M | |
| Common Stock Shares Outstanding | 1.9M | 4.0M | 29.8M | 34.5M | 35.5M | 37.2M | |
| Non Current Liabilities Total | 79.5M | 70.1M | 1.6M | 18.0M | 36.7M | 54.6M | |
| Other Current Assets | 1.6M | 1.5M | 1.2M | 2.8M | 2.4M | 1.5M | |
| Total Liab | 85.0M | 77.6M | 5.8M | 29.7M | 110.5M | 68.7M | |
| Total Current Assets | 6.6M | 8.4M | 115.1M | 93.0M | 86.9M | 48.0M | |
| Short Long Term Debt Total | 79.5M | 70.4M | 1.6M | 14.1M | 43.8M | 52.1M | |
| Net Receivables | 1.9M | 2.6M | 1.5M | 7.2M | 17.4M | 18.2M | |
| Liabilities And Stockholders Equity | 10.5M | 11.2M | 132.9M | 115.5M | 172.3M | 180.9M | |
| Other Stockholder Equity | 171.3M | 192.1M | 394.1M | 428.7M | 461.7M | 484.8M | |
| Short Term Debt | 284K | 889K | 371K | 1.4M | 38.2M | 40.2M | |
| Short Term Investments | 31.4M | 3.3M | 0.0 | 17.4M | 24.7M | 14.7M | |
| Inventory | 1.0 | 224K | 109K | 24.1M | 27.7M | 29.1M | |
| Current Deferred Revenue | 3.8M | 5.5M | 2.5M | 4.7M | 8.3M | 5.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.